ErpeCream® Successfully Completes ICH Zone 4B Stability Programme
Long-term stability studies confirm the robustness of ErpeCream® under demanding climatic conditions, supporting international distribution and future regulatory activities.
ACS Produzioni Biomed S.r.l. (“ACS Biomed”), an Italian biotechnology company developing innovative topical solutions for Herpes Simplex Virus (HSV) infections, has successfully completed the stability programme for ErpeCream® in accordance with ICH Zone 4B climatic conditions, representing an important milestone in the industrial development of the company's proprietary formulation.
The stability programme was designed to evaluate the physical, chemical and microbiological integrity of ErpeCream® under environmental conditions representative of hot and humid climates. Completion of the study confirmed the product's stability throughout its validated shelf life, providing additional support for the company's international commercial strategy.
For healthcare products intended for global distribution, stability testing is a fundamental component of product development. Demonstrating that a formulation maintains its quality and performance under demanding climatic conditions is essential for supporting regulatory documentation, manufacturing consistency and international supply chain management.
Supporting International Distribution
The successful completion of the ICH Zone 4B programme confirms that ErpeCream® maintains its predefined quality characteristics under storage conditions representative of tropical and subtropical regions.
This achievement is particularly relevant as ACS Biomed expands into international markets where elevated temperatures and humidity are routine throughout the year.
The stability data supports the company's ability to supply distributors operating across Europe, Latin America and other international territories while maintaining consistent product quality during storage, transportation and commercial distribution.
Strengthening Product Development
Beyond regulatory requirements, stability studies represent an important indicator of manufacturing quality and formulation robustness.
For ACS Biomed, the completion of the ICH programme reflects the maturity of the company's proprietary nanoemulsion technology and its readiness for large-scale commercial deployment.
The data generated through the programme contributes to the technical documentation supporting future regulatory activities while reinforcing confidence in the reproducibility of the manufacturing process.
Building the Foundation for Global Growth
As ACS Biomed continues to expand internationally, the company remains committed to combining scientific research with high manufacturing standards and regulatory excellence.
The successful completion of the ICH Zone 4B stability programme represents another important milestone in the development of ErpeCream®, strengthening the company's ability to support international distribution while advancing its broader commercial and pharmaceutical strategy.